drugset / Trial / NCT03726398
CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH
Phase 2/3
Withdrawn
Franz Rischard, DO
National Jewish Health · collabUniversity of Pittsburgh · collab
NaSingle-groupOpen-labelPrevention
Summary
Patients with interstitial lung disease (ILD) and scleroderma who develop pulmonary hypertension (PH) do not fit well into the current classification system and treatments for pulmonary hypertension. This study aims to better understand patients with ILD-PH and scleroderma and to determine if treatment with Macitentan is beneficial.
Timeline
- Start
- 2018-09-01
- Primary completion
- 2020-08-03
- Completion
- 2020-08-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Macitentan | Other / unclassified | 10 mg | Oral |